Ascentage Pharma announced that it has released the results of lisaftoclax, one of the company’s key drug candidates, in patients with treatment-naïve or relapsed/refractory acute myeloid leukemia or other myeloid neoplasms, in a Poster Presentation at the 65th American Society of Hematology Annual Meeting, taking place in San Diego, CA, the United States.
